Are unique LONG-ACTING GLYCOPEPTIDES agents. Pharmacologically, they start with the base structure of a glycopeptide and add structural characteristics that slow their elimination. Both can be dosed intravenously just once for the equivalent of 2 weeks of therapy since each has a half-life of over a week.
Therapeutic Uses: Both drugs have strictly gram-positive activity that includes MRSA and streptococci. Used in Skin and skin structure infections in patients whose infections are either known or highly suspected to be caused by gram-positive organisms.
Side Effects: Nausea, vomiting, diarrhea, and rash were the most common adverse effects with both drugs.